• Bibiloni R , FedorakRN, TannockGW, MadsenKL, GionchettiP, CampieriM, De SimoneC & SartorRB (2005) VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol100: 15391546.
    Direct Link:
  • Borruel N , CarolM, CasellasF, AntolínM, de LaraF, EspínE, NavalJ, GuarnerF & MalageladaJR (2002) Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut51: 659664.
  • Bouma G & StroberW (2003) The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol3: 521533.
  • Cella M , DöhringC, SamaridisJ, DessingM, BrockhausM, LanzavecchiaA & ColonnaM (1997) A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med185: 17431751.
  • Christensen HR , FrøkiaerH & PestkaJJ (2002) Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol168: 171178.
  • Coombes JL & PowrieF (2008) Dendritic cells in intestinal immune regulation. Nat Rev Immunol8: 435446.
  • Drakes M , BlanchardT & CzinnS (2004) Bacterial probiotic modulation of dendritic cells. Infect Immun72: 32993309.
  • Foligne B , NuttenS, GrangetteC, DenninV, GoudercourtD, PoiretS, DewulfJ, BrassartD, MercenierA & PotB (2007a) Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J Gastroentero13: 236243.
  • Foligne B , ZoumpopoulouG & DewulfJ (2007b) A key role of dendritic cells in probiotic functionality. PLoS One2: e313.
  • Fuss IJ , BeckerC, YangZ, GrodenC, HornungRL, HellerF, NeurathMF, StroberW & MannonPJ (2006) Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis12: 915.
  • Gionchetti P , RizzelloF, HelwigU, VenturiA, LammersKM, BrigidiP, VitaliB, PoggioliG, MiglioliM & CampieriM (2003) Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124: 12021209.
  • Goriely S , NeurathMF & GoldmanM (2008) How microorganisms tip the balance between interleukin-12 family members. Nat Rev Immunol8: 8186.
  • Guslandi M , MezziG, SorghiM & TestoniPA (2000) Saccharomyces boulardii in maintenance treatment of Crohn's disease. Digest Dis Sci45: 14621464.
  • Guslandi M , GiolloP & TestoniPA (2003) A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroen Hepat15: 697698.
  • Hart AL , LammersK, BrigidiPet al. (2004) Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut53: 16021609.
  • Jensen SJ & GadM (2010) Differential induction of inflammatory cytokines by dendritic cells treated with novel TLR-agonist and cytokine based cocktail: targeting dendritic cells in autoimmunity. J Inflamm 7: 37.
  • Kim HJ , CamilleriM, McKinzieS, LempkeMB, BurtonDD, ThomfordeGM & ZinsmeisterAR (2003) A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharm Therap17: 895904.
  • Kim HJ , Vazquez RoqueMI, CamilleriM, StephensD, BurtonDD, BaxterK, ThomfordeG & ZinsmeisterAR (2005) A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroent Motil17: 687696.
  • Kobayashi T , OkamotoS, HisamatsuTet al. (2008) IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohns disease. Gut57: 16821689.
  • Konstantinov SR , SmidtH, de VosWM, BruijnsSC, SinghSK, ValenceF, MolleD, LortalS, AltermannE & KlaenhammerTR (2008) S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell functions. P Natl Acad Sci USA105: 1947419479.
  • Kruis W , FricP, PokrotnieksJet al. (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut53: 16171623.
  • Malchow HA (1997) Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease?J Clin Gastroenterol25: 653658.
  • Maupas JL , ChampemontP & DelforgeM (1983) Treatment of irritable bowel syndrome. Double blind trial of Saccharomyces boulardii. Médecine Chirurgie Digestives2: 7779.
  • Mimura T , RizzelloF, HelwigU, PoggioliG, SchreiberS, TalbotIC, NichollsRJ, GionchettiP, CampieriM & KammMA (2004) Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut53: 108114.
  • Neurath MF (2007) IL-23: a master regulator in Crohn disease. Nat Med 13: 2628.
  • Öhman L , IsakssonS, LindmarkAC, PosserudI, StotzerPO, StridH, SjövallH & SimrénM (2009) T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol104: 12051212.
  • O'Mahony L , McCarthyJ, KellyP, HurleyG, LuoF, ChenK, O'SullivanGC, KielyB, CollinsJK & ShanahanF (2005) Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128: 541551.
  • Paineau D , CarcanoD, LeyerG, DarquyS, AlyanakianMA, SimoneauG, BergmannJF, BrassartD, BornetF & OuwehandAC (2008) Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. FEMS Immunol Med Mic 53: 107113.
  • Pamer EG (2007) Immune responses to commensal and environmental microbes. Nat Immunol11: 11731178.
  • Plassmann D & Schulte-WitteH (2007) Treatment of irritable bowel syndrome with Escherichia coli strain Nissle 1917 (EcN): a retrospective survey. Med Klin 102: 888892.
  • Pothoulakis C , KellyCP, JoshiMA, GaoN, O'KeaneCJ, CastagliuoloI & LamontJT (1993) Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology104: 11081115.
  • Rembacken BJ , SnellingAM, HawkeyPM, ChalmersDM & AxonAT (1999) Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354: 635639.
  • Round JL & MazmanianSK (2009) The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol9: 313323.
  • Shortman K & NaikSH (2007) Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol7: 1930.
  • Sokol H , PigneurB, WatterlotLet al. (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. P Natl Acad Sci USA105: 1673116736.
  • Steidler L , HansW, SchotteL, NeirynckS, ObermeierF, FalkW, FiersW & RemautE (2000) Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science289: 13521355.
  • Tasteyre A , BarcMC, KarjalainenT, BourliouxP & CollignonA (2002) Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii. Microb Pathogenesis5: 219225.
  • Thomas S , PrzesdzingI, MetzkeD, SchmitzJ, RadbruchA & BaumgartDC (2009) Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation. Clin Exp Immunol156: 7887.
  • Tursi A (2004) Acute diverticulitis of the colon – current medical therapeutic management. Expert Opin Pharmaco5: 5559.
  • Vanderpool C , YanF & PolkDB (2008) Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel diseases. Inflamm Bowel Dis 14: 15851596.
  • Wang L , Pino-LagosK, de VriesVC, GuleriaI, SayeghMH & NoelleRJ (2008) Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+regulatory T cells. P Natl Acad Sci USA105: 93319336.
  • Whorwell PJ , AltringerL, MorelJ, BondY, CharbonneauD, O'MahonyL, KielyB, ShanahanF & QuigleyEM (2006) Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol101: 15811590.
    Direct Link:
  • Zeuthen LH , ChristensenHR & FrøkiaerH (2006) Lactic acid bacteria inducing a weak interleukin-12 and tumor necrosis factor alpha response in human dendritic cells inhibit strongly stimulating lactic acid bacteria but act synergistically with gram-negative bacteria. Clin Vaccine Immunol13: 365375.
  • Zhang Y , ChungY, BishopCet al. (2006) Regulation of T cell activation and tolerance by PDL2. P Natl Acad Sci USA103: 1169511700.